Blog

ICH M12 Step 4 transforms human hepatocytes DDI studies with standardized protocols, risk-based assessment, and no animal validation. Use plateable hepatocytes for CYP1A2/2C19/3A4 phenotyping, P-gp/BCRP transport, and mRNA induction via PCR. Preci delivers guideline-compliant models.

Microsome pooling challenges like particle size variation, genetic polymorphisms, and liver ischemia degrade assay reproducibility. Preci addresses these with genetic screening, optimized cryopreservation, and ready-to-use preplated formats. Get stable, scalable human liver microsomes for metabolic stability testing.

Human hepatocytes assays deliver critical ADME-Tox insights for drug safety and metabolism. Compare microsomes (high-throughput clearance), pooled suspension (Phase I/II stability), plateable (CYP induction, 1-week culture), and spheroids (4-week low-clearance studies). Preci's diverse portfolio—including isogenic NPC—powers reproducible preclinical predictions.

ExVivoGel beats Matrigel for organoid/spheroid research. Sourced from human sarcoma (liver fibrosis/tumor options available), it matches real tissue complexity perfectly. Order from Preci today!

Human-derived cell models are revolutionizing predictive drug activity assays, improving translation from conventional cell lines and animal studies. For instance, immortalized cell lines exhibit genomic instability, whereas real tissues require complexity.